Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 4/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965739 | 0.82 | ATR (0.45) | BRD9LCKRXFP1METAP1CYP17A1 | |
| SCHEMBL11887395 | 0.81 | METAP1 (0.39) | BRD9RXFP1METAP1CYP17A1ATR | |
| SCHEMBL546220 | 0.81 | METAP1 (0.39) | BRD9RXFP1METAP1CYP17A1ATR | |
| SCHEMBL20268056 | 0.80 | CYP17A1 (0.37) | BRD9RXFP1METAP1CYP17A1ATR | |
| SCHEMBL10280188 | 0.80 | CYP17A1 (0.37) | BRD9RXFP1METAP1CYP17A1ATR | |
| SCHEMBL12583021 | 0.80 | ATR (0.43) | BRD9LCKRXFP1METAP1CYP17A1 | |
| SCHEMBL21573839 | 0.78 | ALDH1A1 (0.55) | — | |
| SCHEMBL21567562 | 0.77 | GFER (0.41) | BRD9RXFP1METAP1CYP17A1ATR | |
| SCHEMBL8262317 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL28256351 | 0.77 | LCK (0.39) | BRD9LCKCYP17A1ATRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728238-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | Nodthera Limited (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| WO-2009089042-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | BRD9 2319/4885LCK 43/4885RXFP1 2304/4885 |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK3, CDK1, AURKA | BRD9 1237/4885LCK 298/4885RXFP1 4155/4885 |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | LDHA, LDHB, PDK4 | BRD9 4101/4885LCK 997/4885RXFP1 970/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | BRD9 4644/4885LCK 2466/4885RXFP1 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.